Researchers have identified how and where in the genome a cancer chemotherapy agent acts on and "un-silences" the epigenetically silenced gene that causes Angelman syndrome, a rare neurodevelopmental ...
New research on the genetics of Prader-Willi and Angelman syndromes could help in developing personalised therapies for associated mental illness and autism features. Prader-Willi syndrome (PWS) and ...
Recent data suggest that a chemotherapy agent used to treat metastatic cancers may also be therapeutic for Angelman or Prader-Willi syndrome, according to researchers. “What determines whether you ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, No. 19 (May 8, 2012), pp. 7403-7408 (6 pages) The Prader-Willi syndrome/Angelman syndrome (PWS/AS) imprinted ...
A newly developed test to screen for three rare genetic disorders simultaneously in newborns was feasible, reliable and scalable, according to a new study. The research, led by the Murdoch Children's ...
Patients with duplication of the proximal long arm of chromosome 15 have been reported in several publications [1], and inv dup(15) which is used to define the psu dic(15;15) marker chromosomes is one ...
A newly developed test to screen for three rare genetic disorders simultaneously in newborns was feasible, reliable and scalable, according to a new study. The research, led by the Murdoch Children’s ...
REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, ...
William Edberg smiles as he takes a a bite of his favorite meal, macaroni and cheese, on Saturday, Feb. 4, 2023, in his Rosemount, Minnesota, home. Born with Angelman syndrome, a rare neurogenetic ...
Researchers have found that Prader-Willi syndrome -- a genetic disorder best known for causing an insatiable appetite that can lead to morbid obesity -- is associated with the loss of non-coding RNAs, ...
Soleno Therapeutics Inc. (NASDAQ: SLNO) pulled off in a major way its randomized-withdrawal phase III study with DCCR (diazoxide choline) in Prader-Willi syndrome, boosting the shares by $22.37, or ...
(SACRAMENTO, Calif.) -- UC Davis researchers have identified how and where in the genome a cancer chemotherapy agent acts on and 'un-silences' the epigenetically silenced gene that causes Angelman ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback